All Stories

  1. Targeting Inflammatory Imbalance in Chronic Kidney Disease: Focus on Anti-Inflammatory and Resolution Mediators
  2. Phospholipid esters from herring roe promotes SPM biosynthesis in human monocyte-derived macrophages and a keratinocyte/fibroblast co-culture with implications for the treatment of psoriasis
  3. Pre-stimulation of Precision-Cut bovine udder slices with zymosan before LPS exposure indicates indicators for trained immunity
  4. Development and Validation of Methodologies for the Identification of Specialized Pro-Resolving Lipid Mediators and Classic Eicosanoids in Biological Matrices
  5. The endocannabinoid anandamide activates pro‐resolving pathways in human primary macrophages by engaging both CB2 and GPR18 receptors
  6. LGR6 frameshift variant abrogates receptor expression on select leukocyte subsets and associates with viral infections
  7. Resolvin D2 prevents vascular remodeling, hypercontractility and endothelial dysfunction in obese hypertensive mice through modulation of vascular and proinflammatory factors
  8. Resolvin T4 enhances macrophage cholesterol efflux to reduce vascular disease
  9. Efferocyte‐Derived MCTRs Metabolically Prime Macrophages for Continual Efferocytosis via Rac1‐Mediated Activation of Glycolysis
  10. Reply to: Failure to apply standard limit-of-detection or limit-of-quantitation criteria to specialized pro-resolving mediator analysis incorrectly characterizes their presence in biological samples
  11. Maresin 1 activates brown adipose tissue and promotes browning of white adipose tissue in mice
  12. Author Correction: A mosquito lipoxin/lipocalin complex mediates innate immune priming in Anopheles gambiae
  13. Mistakes in the re-analysis of lipidomic data obtained from a human model of resolving inflammation lead to erroneous conclusions
  14. Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin intervention
  15. Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis
  16. Resolution Pharmacology: Focus on Pro-Resolving Annexin A1 and Lipid Mediators for Therapeutic Innovation in Inflammation
  17. Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans
  18. Deletion of macrophage Gpr101 disrupts their phenotype and function dysregulating host immune responses in sterile and infectious inflammation
  19. Resolvin D2 Attenuates Cardiovascular Damage in Angiotensin II-Induced Hypertension
  20. Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by Porphyromonas gingivalis
  21. Vagus nerve stimulation promotes resolution of inflammation by a mechanism that involves Alox15 and requires the α7nAChR subunit
  22. Distinct immune profiles of HIV‐infected subjects are linked to specific lipid mediator signature
  23. MCTR3 reprograms arthritic monocytes to upregulate Arginase-1 and exert pro-resolving and tissue-protective functions in experimental arthritis
  24. Evidence for the presence and diagnostic utility of SPM in human peripheral blood
  25. Polyunsaturated fatty acids and fatty acid-derived lipid mediators: Recent advances in the understanding of their biosynthesis, structures, and functions
  26. Utility of the Specialized Pro-Resolving Mediators as Diagnostic and Prognostic Biomarkers in Disease
  27. Lipid mediator n‐3 docosapentaenoic acid‐derived protectin D1 enhances synaptic inhibition of hippocampal principal neurons by interaction with a G‐protein‐coupled receptor
  28. 20‐hydroxyeicosatetraenoic acid (20‐HETE) is a pivotal endogenous ligand for TRPV1‐mediated neurogenic inflammation in the skin
  29. Aspirin activates resolution pathways to reprogram T cell and macrophage responses in colitis-associated colorectal cancer
  30. Lipoxins modulate neutrophil oxidative burst, integrin expression and lymphatic transmigration differentially in human health and atherosclerosis
  31. Stereoselective Synthesis, Configurational Assignment and Biological Evaluations of the Lipid Mediator RvD2 n‐3 DPA
  32. Differential Lipid Mediator Involvement in the Different Forms of Genetic Frontotemporal Dementia: Novel Insights into Neuroinflammation
  33. Lipid Mediator n-3 Docosapentaenoic Acid-Derived Protectin D1­(PD1n-3DPA) Enhances Synaptic Inhibition of Hippocampal Principal Neurons by Interaction with a G-Protein Coupled Receptor
  34. Dysregulated Maresin Concentrations in Plasma and Nasal Secretions From Patients With Chronic Rhinosinusitis
  35. Dysregulated plasma lipid mediator profiles in critically ill COVID-19 patients
  36. Disrupted Resolution Mechanisms Favor Altered Phagocyte Responses in COVID-19
  37. Differential sensitivity of inflammatory macrophages and alternatively activated macrophages to ferroptosis
  38. Loss of 15-lipoxygenase disrupts Treg differentiation altering their pro-resolving functions
  39. 14,17,18-Trihydroxy-Eicosatetraenoic Acid: A Novel Pro-Resolving Lipid Mediator from Marine Microalgae
  40. Platelets orchestrate the resolution of pulmonary inflammation in mice by T reg cell repositioning and macrophage education
  41. Changes in brown adipose tissue lipid mediator signatures with aging, obesity, and DHA supplementation in female mice
  42. Splenic Nerve Neuromodulation Reduces Inflammation and Promotes Resolution in Chronically Implanted Pigs
  43. Protective activities of distinct omega-3 enriched oils are linked to their ability to upregulate specialized pro-resolving mediators
  44. HIF1α activation in dendritic cells under sterile conditions promotes an anti-inflammatory phenotype through accumulation of intracellular lipids
  45. Methodologies and Procedures Employed in the Identification and Quantitation of Lipid Mediators via LC-MS/MS
  46. Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis
  47. The GPR40 Agonist GW9508 Enhances Neutrophil Function to Aid Bacterial Clearance During E. coli Infections
  48. Editorial: Role of Blood Cells in Inflammatory and Vascular Disorders
  49. RvE1 Attenuates Polymicrobial Sepsis-Induced Cardiac Dysfunction and Enhances Bacterial Clearance
  50. Treatment With a Marine Oil Supplement Alters Lipid Mediators and Leukocyte Phenotype in Healthy Patients and Those With Peripheral Artery Disease
  51. ANGPTL3 deficiency alters the lipid profile and metabolism of cultured hepatocytes and human lipoproteins
  52. Imbalance of proresolving lipid mediators in persistent allodynia dissociated from signs of clinical arthritis
  53. Immune Regulatory Mediators in Plasma from Patients With Acute Decompensation Are Associated With 3-Month Mortality
  54. A combination of LCPUFA ameliorates airway inflammation in asthmatic mice by promoting pro-resolving effects and reducing adverse effects of EPA
  55. Lipid mediators of inflammation and Resolution in individuals with tuberculosis and tuberculosis-Diabetes
  56. Enzymatic studies with 3-oxa n-3 DPA
  57. Plant‐ and Fish‐Derived n‐3 PUFAs Suppress Citrobacter Rodentium –Induced Colonic Inflammation
  58. Stereoselective synthesis of MaR2n-3 DPA
  59. Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway
  60. Enriched Marine Oil Supplements Increase Peripheral Blood Specialized Pro-Resolving Mediators Concentrations and Reprogram Host Immune Responses
  61. A Single Injection of Docosahexaenoic Acid Induces a Pro-Resolving Lipid Mediator Profile in the Injured Tissue and a Long-Lasting Reduction in Neurological Deficit after Traumatic Brain Injury in Mice
  62. GPR101 mediates the pro-resolving actions of RvD5n-3 DPA in arthritis and infections
  63. Addendum: Resolving Inflammation: Synthesis, Configurational Assignment, and Biological Evaluations of RvD1 n −3 DPA
  64. Proresolving Mediators LXB4 and RvE1 Regulate Inflammation in Stromal Cells from Patients with Shoulder Tendon Tears
  65. Proresolving mediator profiles in cerebrospinal fluid are linked with disease severity and outcome in adults with tuberculous meningitis
  66. Polyunsaturated fatty acids modify the extracellular vesicle membranes and increase the production of proresolving lipid mediators of human mesenchymal stromal cells
  67. Synthesis, Structural Confirmation, and Biosynthesis of 22-OH-PD1n-3 DPA
  68. Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarction
  69. Lipid mediators in platelet concentrate and extracellular vesicles: Molecular mechanisms from membrane glycerophospholipids to bioactive molecules
  70. Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by Porphyromonas gingivalis
  71. 15-Epi-LXA4 and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture
  72. Tendon cells isolated from patients with persistent shoulder tendinopathy show dysregulated resolution responses
  73. Resolvin D1 Attenuates the Organ Injury Associated With Experimental Hemorrhagic Shock
  74. Pro-Resolving Mediator Profiles And 5-Lipoxygenase Activity In Cerebrospinal Fluid Correlate with Disease Severity and Outcome in Adults with Tuberculous Meningitis
  75. Proresolving mediators LXB4 and RvE1 regulate inflammation in stromal cells from patients with shoulder tendon tears
  76. FRI-109-Increased plasma leukotriene B4 in decompensated cirrhosis associates with disease progression and leads to increased skin window neutrophil infiltration
  77. Leukocytes from obese individuals exhibit an impaired SPM signature
  78. Novel n-3 Docosapentaneoic Acid-Derived Pro-resolving Mediators Are Vasculoprotective and Mediate the Actions of Statins in Controlling Inflammation
  79. Resolving Inflammation: Synthesis, Configurational Assignment, and Biological Evaluations of RvD1 n −3 DPA
  80. New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration
  81. ERV1/ChemR23 Signaling Protects Against Atherosclerosis by Modifying Oxidized Low-Density Lipoprotein Uptake and Phagocytosis in Macrophages
  82. n-3 Docosapentaenoic acid-derived protectin D1 promotes resolution of neuroinflammation and arrests epileptogenesis
  83. New maresin conjugates in tissue regeneration pathway counters leukotriene D4–stimulated vascular responses
  84. Identification and structure elucidation of the pro‐resolving mediators provides novel leads for resolution pharmacology
  85. PDn-3 DPA Pathway Regulates Human Monocyte Differentiation and Macrophage Function
  86. Albumin Counteracts Immune-Suppressive Effects of Lipid Mediators in Patients With Advanced Liver Disease
  87. Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli–driven acute inflammation
  88. Impaired Production and Diurnal Regulation of Vascular RvD n-3 DPA Increase Systemic Inflammation and Cardiovascular Disease
  89. A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults
  90. Endogenously generated arachidonate‐derived ligands for TRPV1 induce cardiac protection in sepsis
  91. Immunoresolvents signaling molecules at intersection between the brain and immune system
  92. Trypanosoma cruzi Produces the Specialized Proresolving Mediators Resolvin D1, Resolvin D5, and Resolvin E2
  93. Lipid Mediator Metabolomics Via LC-MS/MS Profiling and Analysis
  94. Performance of Mixed Species and Mono-specific Algal Diets for Culture of Larval Western School Prawns, Metapenaeus dalli
  95. Does promoting resolution instead of inhibiting inflammation represent the new paradigm in treating infections?
  96. Resolvins suppress tumor growth and enhance cancer therapy
  97. Pro-Resolving Mediators in Regulating and Conferring Macrophage Function
  98. The novel lipid mediator PD1n-3 DPA: An overview of the structural elucidation, synthesis, biosynthesis and bioactions
  99. Prolonged immune alteration following resolution of acute inflammation in humans
  100. NLRP3 Inflammasome Deficiency Protects against Microbial Sepsis via Increased Lipoxin B4 Synthesis
  101. Increased 15-PGDH expression leads to dysregulated resolution responses in stromal cells from patients with chronic tendinopathy
  102. Microscale arrays for the profiling of start and stop signals coordinating human-neutrophil swarming
  103. Recent advances in the chemistry and biology of anti-inflammatory and specialized pro-resolving mediators biosynthesized from n-3 docosapentaenoic acid
  104. 13-Series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis
  105. Characterizing the anti-inflammatory and tissue protective actions of a novel Annexin A1 peptide
  106. Protectin D1 n-3 DPA and resolvin D5 n-3 DPA are effectors of intestinal protection
  107. Resolving inflammation by using nutrition therapy
  108. Neutrophil Resolvin E1 Receptor Expression and Function in Type 2 Diabetes
  109. Immune resolution mechanisms in inflammatory arthritis
  110. Human Sepsis Eicosanoid and Proresolving Lipid Mediator Temporal Profiles
  111. Vagal Regulation of Group 3 Innate Lymphoid Cells and the Immunoresolvent PCTR1 Controls Infection Resolution
  112. Plasma lipid mediator (LM) profiling identifies hyper- and hypo-activated groups of patients with ACLF and targeted 20% human albumin solution infusion recalibrates abnormalities
  113. Stereocontrolled synthesis and investigation of the biosynthetic transformations of 16(S),17(S)-epoxy-PDn-3 DPA
  114. Identification and Actions of the Maresin 1 Metabolome in Infectious Inflammation
  115. Carbon Monoxide Improves Efficacy of Mesenchymal Stromal Cells During Sepsis by Production of Specialized Proresolving Lipid Mediators*
  116. Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans
  117. Synthesis of 13(R)-Hydroxy-7Z,10Z,13R,14E,16Z,19Z Docosapentaenoic Acid (13R-HDPA) and Its Biosynthetic Conversion to the 13-Series Resolvins
  118. Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages
  119. Signaling and Immunoresolving Actions of Resolvin D1 in Inflamed Human Visceral Adipose Tissue
  120. Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation
  121. Aspirin-triggered resolvin D1 is produced during self-resolving gram-negative bacterial pneumonia and regulates host immune responses for the resolution of lung inflammation
  122. Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses
  123. Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Protective for Injured Epithelia
  124. Macrophage Proresolving Mediators—the When and Where
  125. Human milk proresolving mediators stimulate resolution of acute inflammation
  126. SPM in CAD and clot remodeling
  127. Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis
  128. Lipid mediators and the resolution of chronic inflammation: implications for arthritis therapy
  129. The Protectin PCTR1 Is Produced by Human M2 Macrophages and Enhances Resolution of Infectious Inflammation
  130. Identification and Actions of a Novel Third Maresin Conjugate in Tissue Regeneration: MCTR3
  131. Resolvin D4 stereoassignment and its novel actions in host protection and bacterial clearance
  132. Selective identification of specialized pro-resolving lipid mediators from their biosynthetic double di-oxygenation isomers
  133. Specialized Pro-Resolving Mediators from Omega-3 Fatty Acids Improve Amyloid-β Phagocytosis and Regulate Inflammation in Patients with Minor Cognitive Impairment
  134. Maresin 1 Biosynthesis and Proresolving Anti-infective Functions with Human-Localized Aggressive Periodontitis Leukocytes
  135. Human Periodontal Stem Cells Release Specialized Proresolving Mediators and Carry Immunomodulatory and Prohealing Properties Regulated by Lipoxins
  136. Synthesis of the 16S,17S-Epoxyprotectin Intermediate in the Biosynthesis of Protectins by Human Macrophages
  137. Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages
  138. Specialized Pro-Resolving Mediators from Omega-3 Fatty Acids Improve Amyloid-β Phagocytosis and Regulate Inflammation in Patients with Minor Cognitive Impairment
  139. The Regulation of Proresolving Lipid Mediator Profiles in Baboon Pneumonia by Inhaled Carbon Monoxide
  140. Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections
  141. Identification of resolvin D2 receptor mediating resolution of infections and organ protection
  142. Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function
  143. Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease
  144. A mosquito lipoxin/lipocalin complex mediates innate immune priming in Anopheles gambiae
  145. Proresolving actions of a new resolvin D1 analog mimetic qualifies as an immunoresolvent
  146. The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution
  147. Characterization of the anti-inflammatory properties of NCX 429, a dual-acting compound releasing nitric oxide and naproxen
  148. Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome
  149. Novel proresolving and tissue-regenerative resolvin and protectin sulfido-conjugated pathways
  150. Cutting Edge: Maresin-1 Engages Regulatory T Cells To Limit Type 2 Innate Lymphoid Cell Activation and Promote Resolution of Lung Inflammation
  151. Cell-cell interactions and bronchoconstrictor eicosanoid reduction with inhaled carbon monoxide and resolvin D1
  152. Proresolving Nanomedicines Activate Bone Regeneration in Periodontitis
  153. Maresin 1 biosynthesis during platelet–neutrophil interactions is organ-protective
  154. Lipid Mediators in the Resolution of Inflammation
  155. Correction: Corrigendum: Novel n-3 Immunoresolvents: Structures and Actions
  156. Identification of 14-series sulfido-conjugated mediators that promote resolution of infection and organ protection
  157. Plasma Metabolomics in Human Pulmonary Tuberculosis Disease: A Pilot Study
  158. Aging Delays Resolution of Acute Inflammation in Mice: Reprogramming the Host Response with Novel Nano-Proresolving Medicines
  159. Total Synthesis of the Anti-inflammatory and Pro-resolving Lipid Mediator MaR1n−3 DPAUtilizing an sp3-sp3Negishi Cross-Coupling Reaction
  160. Synthesis and Anti-inflammatory and Pro-resolving Activities of 22-OH-PD1, a Monohydroxylated Metabolite of Protectin D1
  161. Total Synthesis of the Anti-inflammatory and Pro-resolving Lipid Mediator MaR1n−3 DPAUtilizing an sp3-sp3Negishi Cross-Coupling Reaction
  162. Maresin Biosynthesis and Identification of Maresin 2, a New Anti-Inflammatory and Pro-Resolving Mediator from Human Macrophages
  163. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue
  164. Cutting Edge: Parathyroid Hormone Facilitates Macrophage Efferocytosis in Bone Marrow via Proresolving Mediators Resolvin D1 and Resolvin D2
  165. Vagus nerve controls resolution and pro-resolving mediators of inflammation
  166. Total Synthesis of the Lipid Mediator PD1n-3 DPA: Configurational Assignments and Anti-inflammatory and Pro-resolving Actions
  167. Investigational Analysis Reveals a Potential Role for Neutrophils in Giant-Cell Arteritis Disease Progression
  168. Stereoselective synthesis of protectin D1: a potent anti-inflammatory and proresolving lipid mediator
  169. Microparticle alpha-2-macroglobulin enhances pro-resolving responses and promotes survival in sepsis
  170. Plasticity of Leukocytic Exudates in Resolving Acute Inflammation Is Regulated by MicroRNA and Proresolving Mediators
  171. Contributions of the Three CYP1 Monooxygenases to Pro-Inflammatory and Inflammation-Resolution Lipid Mediator Pathways
  172. Microparticles are novel effectors of immunity
  173. Heterogeneity in Neutrophil Microparticles Reveals Distinct Proteome and Functional Properties
  174. Inhaled Carbon Monoxide Accelerates Resolution of Inflammation via Unique Proresolving Mediator–Heme Oxygenase-1 Circuits
  175. Proresolving and Tissue-Protective Actions of Annexin A1–Based Cleavage-Resistant Peptides Are Mediated by Formyl Peptide Receptor 2/Lipoxin A4 Receptor
  176. Novel n-3 Immunoresolvents: Structures and Actions
  177. The novel 13 S ,14 S ‐epoxy‐maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A 4 hydrolase (LTA 4 H), and shifts macropha...
  178. Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Potent Immunoresolvents
  179. Biphasic Modulation of NOS Expression, Protein and Nitrite Products by Hydroxocobalamin Underlies Its Protective Effect in Endotoxemic Shock: Downstream Regulation of COX-2, IL-1β, TNF-α, IL-6, and HMGB1 Expression
  180. Gene expression signature-based approach identifies a pro-resolving mechanism of action for histone deacetylase inhibitors
  181. Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions
  182. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC–MS/MS
  183. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators
  184. Self-Limited versus Delayed Resolution of Acute Inflammation: Temporal Regulation of Pro-Resolving Mediators and MicroRNA
  185. Genetic Ablation of the Fpr1 Gene Confers Protection from Smoking-Induced Lung Emphysema in Mice
  186. Resolvin D1 and Resolvin D2 Govern Local Inflammatory Tone in Obese Fat
  187. Resolvin D1 Limits Polymorphonuclear Leukocyte Recruitment to Inflammatory Loci
  188. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages
  189. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain
  190. Annexin A1 N-Terminal Derived Peptide Ac2-26 Exerts Chemokinetic Effects on Human Neutrophils
  191. Annexin A1 regulates neutrophil clearance by macrophages in the mouse bone marrow
  192. Evidence for an Anti-Inflammatory Loop Centered on Polymorphonuclear Leukocyte Formyl Peptide Receptor 2/Lipoxin A4 Receptor and Operative in the Inflamed Microvasculature
  193. Corrections: Anti-Inflammatory Role of the Murine Formyl-Peptide Receptor 2: Ligand-Specific Effects on Leukocyte Responses and Experimental Inflammation
  194. 561 THE CINOD NCX 429 INHIBITS MICROVASCULAR INFLAMMATION THROUGH ITS NO-RELEASING PROPERTIES
  195. Downstream Gene Activation of the Receptor ALX by the Agonist Annexin A1
  196. Design and characterization of a cleavage-resistant Annexin A1 mutant to control inflammation in the microvasculature
  197. CFTR Inhibition Provokes an Inflammatory Response Associated with an Imbalance of the Annexin A1 Pathway
  198. FPR2/ALX receptor expression and internalization are critical for lipoxin A4and annexin‐derived peptide‐stimulated phagocytosis
  199. Anti-Inflammatory Role of the Murine Formyl-Peptide Receptor 2: Ligand-Specific Effects on Leukocyte Responses and Experimental Inflammation
  200. Exploiting the Annexin A1 pathway for the development of novel anti‐inflammatory therapeutics
  201. Functional and Ultrastructural Analysis of Annexin A1 and Its Receptor in Extravasating Neutrophils during Acute Inflammation
  202. Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles
  203. Activation of the annexin 1 counter-regulatory circuit affords protection in the mouse brain microcirculation